Safety/Efficacy Featured Articles

  1. Lilly Makes It Easier For Physicians To Become Investigators 11/10/2016

    As the global head of clinical innovation for Eli Lilly and Company, Katherine Vandebelt knows there are many things pharma needs to do better. No drug can make it to market without first navigating the clinical trials process, which creates a burden on the physicians involved. Therefore, it should come as no surprise to anyone involved in the process that many physicians will oversee one trial and then opt to no longer take part in them.

  2. Are Outdated Pricing Models Hurting Clinical Research? 11/8/2016

    Two issues that always seem to throw a wrench into sponsor/CROs relationships are changes to staffing and pricing. Protocol changes can disrupt trials for CROs and cause price increases for sponsors. Staffing changes can create new learning curves, delay trials, and cause sponsors to feel they were misled. Are penalties an easy way to fix both?

  3. UPS Expands Clinical Life Science Opportunities With Marken Acquisition 11/7/2016

    UPS has entered into a definitive purchase agreement to acquire Marken, a global, privately-held provider of supply chain solutions to the life sciences industry. The transaction, which provides UPS with growth opportunities across the life sciences customer base, is expected to close by December 31, 2016, subject to customary conditions and regulatory approvals.

  4. Clinical News Roundup: FDA Updates Guidance On Race/Ethnicity 11/3/2016

    Clinical news roundup for the week of October 31, 2016 with information on FDA guidance related to race and ethnicity in clinical trials, DIA’s patient engagement study, Parkinson’s Disease Foundation funding research, age and thyroid cancer treatments, and Merck’s success with Alzheimer’s disease.

  5. Clinical Staff Shortage: “Growing Plague” For Pharma & CROs 11/2/2016

    Anyone involved with clinical trials knows a continuing and growing problem in the industry is the lack of qualified clinical research staff. A new report from BioPharm Insight (BPI) acknowledges this trend, noting the staff shortage is a “growing plague to the CRO industry which will need to be addressed in order to ease liabilities.”

  6. Clinical News Roundup: FDA Approves Oncology Trial For Cuban Treatment 10/28/2016

    Clinical news roundup for the week of October 23rd with information on an oncology treatment developed in Cuba, AZ suspending recruitment on two trials, an SCRS white paper on site payments, a new platform for wearables in clinical trials, the CRA shortage, and more.

  7. SCRS: Site/Sponsor Relationship Needs Improvement 10/28/2016

    At the 2016 SCRS (Society for Clinical Research Sites) Global Site Summit, Christine Pierre, president of SCRS, shared the results of a survey conducted of site professionals from around the world. The survey is conducted every year, just prior to the summit, to gauge the opinion of site professionals on various issues and trends. If the results are any indication, there is still room for improvement in sponsor/site relationships.

  8. PatientsLikeMe And Duke Bring Novel Approach To ALS Trial 10/26/2016

    Can the peptide Lunasin help to reverse the debilitating effects of ALS? After one patient (and three experts) noted it could, PatientsLikeMe and the Duke ALS Clinic decided to get involved. Their novel trial will feature an unlimited number of patients, sharing of all patient data, and electronic patient reported outcomes. It also eliminated the use of a placebo.

  9. Clinical News Roundup: Sanofi Invests To Bring Clinical Trials Home 10/23/2016

    Clinical news roundup for the week of October 21, 2016 with information on Sanofi and Science 37 bringing clinical trials to the home, SCRS Eagle Award winners, a precision master trial for AML, promoting trials to patients, stopping the progression of Alzheimer’s disease, and more.

  10. The Benefits Of Outsourcing Clinical Regulatory Requirements 10/20/2016

    When I sat down to speak with Paul Bridges, Ph.D., corporate VP and Interim head of PAREXEL Consulting at the 2016 DIA Annual Meeting, we had recently heard the news of Great Britain exiting the European Union. Bridges seemed to take it completely in stride, noting there will always be changes occurring that can disrupt and erect obstacles to your drug development efforts. While we can’t stop them, we can certainly take advantage of the resources available from partners to better navigate them and mitigate their effects.